Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.40
+9.3%
$0.30
$0.22
$3.67
$14.45M2.991.59 million shs336,528 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$3.36
-0.6%
$2.87
$1.10
$6.01
$58.44M1.59420,884 shs162,157 shs
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$1.71
+6.2%
$1.23
$0.51
$2.45
$73.21M0.96310,153 shs269,307 shs
VolitionRx Limited stock logo
VNRX
VolitionRx
$0.66
-6.3%
$0.60
$0.40
$0.94
$68.10M1.2207,438 shs166,366 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
+12.09%+23.33%+2.78%+57.78%-85.88%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
+0.30%+7.99%+3.36%+89.89%+45.69%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-1.23%+5.92%+37.61%+57.84%+123.61%
VolitionRx Limited stock logo
VNRX
VolitionRx
+4.80%-8.10%+27.38%+42.85%+15.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.4298 of 5 stars
3.03.00.00.00.62.51.3
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.0562 of 5 stars
3.61.00.00.02.50.80.6
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.1177 of 5 stars
3.65.00.00.01.11.70.6
VolitionRx Limited stock logo
VNRX
VolitionRx
2.2683 of 5 stars
3.50.00.00.02.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.00
Hold$11.252,681.21% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.20
Buy$28.50748.21% Upside
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
3.29
Buy$8.00367.84% Upside
VolitionRx Limited stock logo
VNRX
VolitionRx
3.00
Buy$3.50429.50% Upside

Current Analyst Ratings Breakdown

Latest ATHA, VNRX, NRXP, and QNCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
6/20/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/13/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/10/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$3.00
6/6/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/4/2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
5/16/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/30/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/30/2025
VolitionRx Limited stock logo
VNRX
VolitionRx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/29/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$1.16 per shareN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/A($1.48) per shareN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/A$0.69 per shareN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
$1.31M52.05N/AN/A($0.11) per share-6.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%7/30/2025 (Estimated)
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$56.83M-$1.39N/AN/AN/AN/A-117.52%-34.22%8/12/2025 (Estimated)
VolitionRx Limited stock logo
VNRX
VolitionRx
-$35.32M-$0.27N/AN/A-2,321.14%N/A-163.39%N/A

Latest ATHA, VNRX, NRXP, and QNCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million
5/13/2025Q1 2025
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
-$0.24-$0.34-$0.10-$0.34N/AN/A
5/9/2025Q1 2025
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$0.20-$0.23-$0.03-$0.23N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
N/AN/AN/AN/AN/A
VolitionRx Limited stock logo
VNRX
VolitionRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
7.26
7.26
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.22
0.22
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
0.82
4.05
4.05
VolitionRx Limited stock logo
VNRX
VolitionRx
N/A
0.22
0.22

Institutional Ownership

CompanyInstitutional Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
30.75%
VolitionRx Limited stock logo
VNRX
VolitionRx
8.09%

Insider Ownership

CompanyInsider Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
22.10%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
19.00%
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
20.30%
VolitionRx Limited stock logo
VNRX
VolitionRx
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
4039.04 million30.41 millionOptionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
217.29 million14.00 millionOptionable
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
6045.47 million36.24 millionOptionable
VolitionRx Limited stock logo
VNRX
VolitionRx
80103.02 million80.80 millionOptionable

Recent News About These Companies

VolitionRX shares hold as Benchmark maintains rating
VolitionRx initiated with a Buy at H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$0.40 +0.03 (+9.32%)
Closing price 03:58 PM Eastern
Extended Trading
$0.40 -0.01 (-2.10%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$3.36 -0.02 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$3.30 -0.05 (-1.64%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Quince Therapeutics stock logo

Quince Therapeutics NASDAQ:QNCX

$1.71 +0.10 (+6.21%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.53%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

VolitionRx stock logo

VolitionRx NYSE:VNRX

$0.66 -0.04 (-6.33%)
Closing price 03:58 PM Eastern
Extended Trading
$0.68 +0.01 (+2.12%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.